Thinly traded nano cap Precipio (PRPO +71.1%) is up on a 20x surge in volume in apparent response to its announcement that several “large laboratories” that completed validation studies of its IV-Cell cytogenetics media and its HemeScreen Assay are “moving towards” placing orders.
On the working capital front, at the end of June it had ~$1.2M in cash while operatations consumed $4.9M during H1. On August 21, it filed a prospectus for the potential sale of up to 1.8M common shares held by Lincoln Park Capital Fund, asking for accelerated SEC review which was denied.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.